Last reviewed · How we verify
BenFin
BenFin is an investigational oncology agent in phase 3 development by the Alliance for Clinical Trials in Oncology.
At a glance
| Generic name | BenFin |
|---|---|
| Sponsor | Alliance for Clinical Trials in Oncology |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Limited publicly available information exists on BenFin's specific mechanism of action. As a phase 3 oncology candidate, it is likely designed to target a specific molecular pathway involved in cancer cell growth or survival, but the exact target and mechanism require further clinical disclosure.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |